False Positive Rifampicin Resistant Report with Xpert Mtb/Rif Assay in Sputum Samples with Bacterial Grade of Low and Very Low: A Case Report

Authors

  • Lucy Obonyo Nyang’au Mount Kenya University
  • Dr. Evans Amukoye Kenya Medical Research Institute
  • Dr. Stanely Kangethe Mount Kenya University
  • Dr. Jackson Onyuka Mount Kenya University

Keywords:

Mycobacterium Tuberculosis, Rifampicin, Tuberculosis, Xpert, Cycle Threshold.

Abstract

Xpert MTB/RIF assay is a molecular technique which detects Mycobacterium tuberculosis (MTB) and rifampicin resistance simultaneously in two hours. Based on the probes cycle threshold (Ct), the assay provides a semi-quantitative MTB detection which is the number of polymerase chain reaction (PCR) cycles required to amplify MTB deoxyribonucleic acid (DNA) to a level which can be detected. MTB detection is reported as High, Medium, Low or Very Low, while rifampicin resistance is reported as detected, not detected or indeterminate. Rifampicin resistant results with low or very low MTB detection grade or indeterminate rifampicin resistant results should be confirmed with a gold standard culture based drug susceptibility testing (DST).

References

Van Rie, A. Mellet, K. John, M.A. Scott, L. Page-Shipp, L. Dansey, H. Victor, T. Warren, R.(2012). False positive rifampicin resistance on Xpert MTB/RIF assay: Case report and clinical implications. International Journal of tuberculosis and Lung Disease, 16(2):206-208

Steingard, K.R. Schiller, I. Horne, D.S. Pai, M. Boehme, C.C. Dendukuri, N. (2014). Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review) Cochrane Database of systematic Review (1) Art. No. CD009593

Lawn, S.D. Zumla, A.I. (2011). Tuberculosis. Lancet. 378:57-72

Centers for Disease Prevention (2013). Availability of an assay for detecting Mycobacterium tuberculosis, including rifampicin resistant strains and considerations for its use. United States. Morbidity and mortality weekly Report (MMWR/MMWR-CDC 62: 821-827

Lippincott, C.K. Miller, M.B. Popowitch, E.B. Hanrahan, C.F. Van Rie, A. (2014). Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States. Clinical Infectious Diseases 59: 189-192. Cross ref, med-line, Google Scholar

Hanrahan, C.F. Theron, G. Bassett, J. Dheda, K. Scott, L. Stevens, W. Sanne, I. Van Rie, A.(2014). Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immune-Suppression. American Journal of Respiratory and Critical Care Medicine, 189(11): 1426-1434

Marlowe, E.M. Norak-Weekley, S.M Cumpio, J. (2011). Evaluation of the Cepheid Xpert MTB/RIF assay, for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. Journal for Clinical Microbiology, 49: 1621-1623

Theron, G. Peter, J. Van Zyl-Smit R. (2011). Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in high HIV prevalence setting. American Journal of Respiratory and Critical Care Medicine, 184: 132-140

Downloads

Published

2018-08-21

How to Cite

Nyang’au, L. O., Amukoye, D. E., Kangethe, D. S., & Onyuka, D. J. (2018). False Positive Rifampicin Resistant Report with Xpert Mtb/Rif Assay in Sputum Samples with Bacterial Grade of Low and Very Low: A Case Report. International Journal of Sciences: Basic and Applied Research (IJSBAR), 40(2), 186–189. Retrieved from https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/9163

Issue

Vol. 40 No. 2 (2018)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.